Stock Scorer

Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences, Inc. reported revenue of 48.1M USD for the quarter ending 30 June 2026, up 5.6% from 45.6M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 48.1M +5.6%
Gross Profit Q2 '26 · ending 30 June 2026 28.3M +18.7%
Operating Income Q2 '26 · ending 30 June 2026 -11.4M —
Net Income Q2 '26 · ending 30 June 2026 -12.2M —
Cost of Revenue Q2 '26 · ending 30 June 2026 19.8M -8.9%
Operating Cash Flow Q2 '26 · ending 30 June 2026 1.4M +1165.7%
Free Cash Flow Q2 '26 · ending 30 June 2026 -849K —
Shares Outstanding Q2 '26 · ending 30 June 2026 129.5M +0.9%
EPS Q4 '22 · ending 31 December 2022 0.04 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 201.5M-40.4M-66.5M-8.8M
20242024-12-31 200.5M-20.5M-6M21.9M
20232023-12-31 193M-27.8M-12.1M633K
20222022-12-31 164M-1.8M2.5M-22M
20212021-12-31 128M9.2M3M266K
20202020-12-31 92.8M13.7M19.4M13.6M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3048.1M
Q1 '262026-03-3144.1M
Q4 '252025-12-3162.1M
Q3 '252025-09-3052.3M
Q2 '252025-06-3045.6M
Q1 '252025-03-3141.5M
Q4 '242024-12-3157.5M
Q3 '242024-09-3051.5M
Q2 '242024-06-3046.6M
Q1 '242024-03-3144.9M
Q4 '232023-12-3158.2M
Q3 '232023-09-3048M
Q2 '232023-06-3049.7M
Q1 '232023-03-3137.1M
Q4 '222022-12-3148.3M
Q3 '222022-09-3040.5M
Q2 '222022-06-3040.2M
Q1 '222022-03-3135.1M
Q4 '212021-12-3138.9M
Q3 '212021-09-3034.4M

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-3028.3M
Q1 '262026-03-3121.3M
Q4 '252025-12-3132.9M
Q3 '252025-09-3027.6M
Q2 '252025-06-3023.9M
Q1 '252025-03-3120.2M
Q4 '242024-12-3133.7M
Q3 '242024-09-3029M
Q2 '242024-06-3025.4M
Q1 '242024-03-3123M
Q4 '232023-12-3133M
Q3 '232023-09-3027.2M
Q2 '232023-06-3028.2M
Q1 '232023-03-3121M
Q4 '222022-12-3129.4M
Q3 '222022-09-3026.9M
Q2 '222022-06-3024.6M
Q1 '222022-03-3120.2M
Q4 '212021-12-3123.6M
Q3 '212021-09-3021.3M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-11.4M
Q1 '262026-03-31-18.5M
Q4 '252025-12-31-5.6M
Q3 '252025-09-30-9.2M
Q2 '252025-06-30-10.6M
Q1 '252025-03-31-15M
Q4 '242024-12-313M
Q3 '242024-09-30-4.2M
Q2 '242024-06-30-8.5M
Q1 '242024-03-31-10.7M
Q4 '232023-12-31-137K
Q3 '232023-09-30-6.4M
Q2 '232023-06-30-9.1M
Q1 '232023-03-31-12.2M
Q4 '222022-12-3184K
Q3 '222022-09-301.4M
Q2 '222022-06-30-891K
Q1 '222022-03-31-2.4M
Q4 '212021-12-311.3M
Q3 '212021-09-302.9M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-12.2M
Q1 '262026-03-31-18.9M
Q4 '252025-12-31-44.1M
Q3 '252025-09-30-5.5M
Q2 '252025-06-30-5.6M
Q1 '252025-03-31-11.4M
Q4 '242024-12-319.6M
Q3 '242024-09-30941K
Q2 '242024-06-30-10.4M
Q1 '242024-03-31-6.2M
Q4 '232023-12-315.5M
Q3 '232023-09-30-6.5M
Q2 '232023-06-30-4.4M
Q1 '232023-03-31-6.8M
Q4 '222022-12-313.5M
Q3 '222022-09-301.6M
Q2 '222022-06-30-702K
Q1 '222022-03-31-2.2M
Q4 '212021-12-310
Q3 '212021-09-301.4M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-3019.8M
Q1 '262026-03-3122.9M
Q4 '252025-12-3129.3M
Q3 '252025-09-3024.7M
Q2 '252025-06-3021.7M
Q1 '252025-03-3121.3M
Q4 '242024-12-3123.8M
Q3 '242024-09-3022.5M
Q2 '242024-06-3021.2M
Q1 '242024-03-3121.8M
Q4 '232023-12-3125.2M
Q3 '232023-09-3020.8M
Q2 '232023-06-3021.5M
Q1 '232023-03-3116.1M
Q4 '222022-12-3119M
Q3 '222022-09-3013.6M
Q2 '222022-06-3015.6M
Q1 '222022-03-3114.9M
Q4 '212021-12-3115.3M
Q3 '212021-09-3013.1M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-301.4M
Q1 '262026-03-31-2.7M
Q4 '252025-12-31-771K
Q3 '252025-09-30-3.9M
Q2 '252025-06-30108K
Q1 '252025-03-31-125K
Q4 '242024-12-312M
Q3 '242024-09-3013.2M
Q2 '242024-06-306.2M
Q1 '242024-03-314M
Q4 '232023-12-319.5M
Q3 '232023-09-30-4.2M
Q2 '232023-06-30-2.9M
Q1 '232023-03-312.9M
Q4 '222022-12-316.2M
Q3 '222022-09-30-7.5M
Q2 '222022-06-30-9.4M
Q1 '222022-03-31-1.5M
Q4 '212021-12-315.4M
Q3 '212021-09-301.2M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-849K
Q1 '262026-03-31-4.9M
Q4 '252025-12-31-1.8M
Q3 '252025-09-30-4.6M
Q2 '252025-06-30-1.5M
Q1 '252025-03-31-974K
Q4 '242024-12-311.1M
Q3 '242024-09-3012.2M
Q2 '242024-06-305.2M
Q1 '242024-03-313.4M
Q4 '232023-12-318M
Q3 '232023-09-30-5.6M
Q2 '232023-06-30-4.2M
Q1 '232023-03-312.4M
Q4 '222022-12-31-337K
Q3 '222022-09-30-8.6M
Q2 '222022-06-30-10.8M
Q1 '222022-03-31-2.3M
Q4 '212021-12-314.2M
Q3 '212021-09-30-147K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30129.5M
Q1 '262026-03-31128.7M
Q3 '252025-09-30127.5M
Q2 '252025-06-30126.9M
Q1 '252025-03-31128.3M
Q3 '242024-09-30132.8M
Q2 '242024-06-30131.4M
Q1 '242024-03-31130.9M
Q3 '232023-09-30136.2M
Q2 '232023-06-30135.9M
Q1 '232023-03-31135.5M
Q3 '222022-09-30138.7M
Q2 '222022-06-30134.4M
Q1 '222022-03-31133.9M
Q3 '212021-09-30113.6M
Q2 '212021-06-3036.2M
Q1 '212021-03-3135.8M
Q3 '202020-09-3031.1M
Q2 '202020-06-3031.1M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q4 '222022-12-310.04
Q3 '222022-09-300.01
Q2 '222022-06-300.02
Q1 '222022-03-310.02
Q4 '212021-12-310.00
Q3 '212021-09-300.01